Protecting children's kidneys from cisplatin by boosting mitochondrial antioxidants
Targeting Tubular Mitochondrial Superoxide Dismutation in Cisplatin Renal Repair
This project uses a mitochondrial antioxidant called GC4419 to try to prevent and repair kidney damage caused by cisplatin chemotherapy in children.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project ID | NIH-11103336 on NIH RePORTER |
What this research studies
If your child is receiving cisplatin chemotherapy, researchers are exploring whether boosting a specific mitochondrial antioxidant can help the kidney recover. The team studies how harmful oxygen molecules in kidney tubule cells disrupt energy production and whether GC4419 restores mitochondrial function and NADPH metabolism. They will use lab models, animal work, and analyses of human samples to find blood or urine biomarkers that predict who benefits. The goal is to stop early injury from becoming long-term kidney disease after cisplatin treatment.
Who could benefit from this research
Good fit: Children receiving cisplatin chemotherapy and who are at risk of or showing early signs of kidney injury would be the ideal candidates.
Not a fit: Patients whose kidney failure is already advanced (end-stage) or whose kidney injury is not related to cisplatin are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could reduce long-term kidney damage from cisplatin and improve kidney repair after chemotherapy.
How similar studies have performed: Preclinical studies in mice and early human data have shown GC4419 can protect kidneys and improve mitochondrial function, though broader clinical validation is still needed.
Where this research is happening
Columbus, United States
- Research Inst Nationwide Children's Hosp — Columbus, United States (Active)
Researchers
- Principal investigator: Zepeda-Orozco, Diana — Research Inst Nationwide Children's Hosp
- Study coordinator: Zepeda-Orozco, Diana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.